

Jubilant Pharma Trading Inc
Balance Sheet as at 31 March 2017

	Notes No	As at 31 March 2017		As at 31 March 2016		As at 1 April 2015	
		USD	(INR'000)	USD	(INR'000)	USD	(INR'000)
ASSETS							
Non-current assets							
Deferred tax assets(net)	1	1,502	97	-	-	-	-
Income tax assets(net)	2	7,234	469	-	-	-	-
Total non-current assets		8,736	566	-	-	-	-
Current assets							
Inventories	3	345,540	22,408	744,493	49,323	1,248,756	78,047
Financial Assets							
Trade receivables	4	3,659,093	237,292	2,476,110	164,042	4,400,790	275,049
Cash and cash equivalents	5	84,252	5,464	116,356	7,709	88,701	5,544
Short-term loans and advances	6	225,000	14,591	225,000	14,906	80,325	5,020
Other current assets	7	13,029	845	5,950	394	-	-
Total current assets		4,326,914	280,600	3,567,909	236,374	5,818,572	363,660
Total Assets		4,335,650	281,166	3,567,909	236,374	5,818,572	363,660
EQUITY AND LIABILITIES							
Equity							
Equity share capital	8	100	6	100	6	100	6
Other equity	9	1,458,513	94,585	1,140,708	75,572	487,663	30,479
Total equity		1,458,613	94,591	1,140,808	75,578	487,763	30,485
Liabilities							
Current liabilities							
Financial liabilities							
Trade payables	10	2,055,658	133,309	1,808,658	119,824	4,786,898	299,181
Other current liabilities	11	-	-	-	-	281,323	17,583
Current tax liabilities(Net)	12	821,379	53,266	618,443	40,972	262,588	16,411
Total current liabilities		2,877,037	186,575	2,427,101	160,796	5,330,809	333,175
Total Equity and Liabilities		4,335,650	281,166	3,567,909	236,374	5,818,572	363,660

Prakash C Bisht
CFO (LSI) & Senior VP (Group Accounts)
Place: Noida
Date: 23 May 2017

Jubilant Pharma Trading Inc
Statement of Profit and Loss for the year ended 31 March 2017

	Notes No	For the year-ended on 31 March 2017		For the year-ended on 31 March 2016	
		USD	(INR'000)	USD	(INR'000)
REVENUE					
Revenue from operations (Gross)	13	18,371,257	1,232,322	19,877,673	1,295,972
Other income	14	4,625	310	6,500	438
Total revenue		18,375,882	1,232,632	19,884,173	1,296,410
EXPENSES					
Purchase of Stock-in-trade	15	17,002,922	1,142,784	17,910,954	1,168,445
Change in inventories of traded Goods	16	398,953	24,510	504,263	32,191
Other expenses	17	454,768	30,508	457,414	29,927
Total expenses		17,856,643	1,197,802	18,872,631	1,230,563
Profit before tax		519,239	34,830	1,011,542	65,847
Tax expenses:					
- Current tax		202,936	13,617	358,497	23,343
- Deferred tax charge/(credit)		(1,502)	(102)		
		201,434	13,515	358,497	23,343
Profit for the year		317,805	21,315	653,045	42,504
Other comprehensive income					
Items that will be reclassified to profit or loss					
Exchange differences on translation of foreign operations		-	(2,302)	-	2,901
Total other comprehensive Income, net of tax		-	(2,302)	-	2,901
Total comprehensive income for the year		317,805	19,013	653,045	45,405

Prakash C Bisht
CFO (LSI) & Senlor VP (Group Accounts)
Place: Noida
Date: 23 May 2017

Jubilant Pharma Trading Inc

Cash flow statement for the Year ended on 31 March 2017

Particulars	For the year ended on 31 March 2017		For the year ended on 31 March 2016	
	USD	(INR'000)	USD	(INR'000)
A. Cash flow from operating activities				
Net profit before tax	519,239	34,830	1,011,542	65,847
Operating cash flow before working capital changes				
Decrease/ (increase) in inventories	398,953	26,754	504,263	32,888
Decrease/ (increase) in trade receivable, loans and advances and other current assets	(1,190,062)	(79,806)	1,774,055	115,704
Increase/ (decrease) in trade payables and other current liabilities	247,000	16,564	(3,259,563)	(212,589)
Cash generated from operations	(24,870)	(1,658)	30,297	1,850
Income tax and wealth tax paid (net of refund)	(7,234)	(485)	(2,642)	(172)
Net cash generated from operating activities	(32,104)	(2,143)	27,655	1,678
B. Effect of exchange rate changes		(102)		487
Net decrease in cash and cash equivalents (A+B)	(32,104)	(2,245)	27,655	2,165
Add: cash and cash equivalents at the beginning of year	116,356	7,709	88,701	5,544
Cash and cash equivalents at the end of the year	84,252	5,464	116,356	7,709
<i>Reconciliation of cash and cash equivalents as per the cash flow statement</i>				
Cash and cash equivalents	84,252	5,464	116,356	7,709
Balances as per statement of cash flows	84,252	5,464	116,356	7,709

Prakash C Bisht

CFO (LSI) & Senior VP (Group Accounts)

Place: Noida

Date: 23 May 2017

Jubilant Pharma Trading Inc

Notes to financial statements for the year 31 March 2017

Particulars	As at 31 March 2017		As at 31 March 2016		As at 1 April 2015	
	USD	(INR'000)	USD	(INR'000)	USD	(INR'000)
1. FINANCIAL ASSETS NON CURRENT						
LONG TERM LOANS AND ADVANCES						
<i>(Unsecured and considered good)</i>						
Deferred tax Assets	1,502	97	-	-	-	-
Deferred tax Assets(Net)	1,502	97	-	-	-	-
2. INCOME TAX ASSETS (NET)						
Advance payment of Income tax (Including TDS)	7,234	469	-	-	-	-
	7,234	469	-	-	-	-
3. INVENTORIES						
<i>(Valued at lower of cost and net realisable value)</i>						
- Stock-in-trade	345,540	22,408	744,493	49,323	1,248,756	78,047
	345,540	22,408	744,493	49,323	1,248,756	78,047
4. TRADE RECEIVABLES						
Other receivables						
Unsecured, considered good	3,659,093	237,292	2,476,110	164,042	4,400,790	275,049
	3,659,093	237,292	2,476,110	164,042	4,400,790	275,049
5. CASH AND CASH EQUIVALENTS						
Cash and cash equivalents						
Balances with banks:						
- On current accounts	84,252	5,464	116,356	7,709	88,701	5,544
	84,252	5,464	116,356	7,709	88,701	5,544
6. SHORT TERM LOANS AND ADVANCES						
<i>(Unsecured and considered good)</i>						
- Loans to related parties	225,000	14,591	225,000	14,906	80,325	5,020
	225,000	14,591	225,000	14,906	80,325	5,020
7. OTHER CURRENT ASSETS						
Loans and advances to employees	-	-	150	10	-	-
Advance for supply of goods and services	8,005	519	-	-	-	-
Prepaid expenses	5,024	326	5,800	384	-	-
	13,029	845	5,950	394	-	-

Jubilant Pharma Trading Inc
Notes to financial statements for the year 31 March 2017

Particulars	As at 31 March 2017		As at 31 March 2016		As at 1 April 2015	
	USD	(INR'000)	USD	(INR'000)	USD	(INR'000)
8. SHARE CAPITAL						
Issued, subscribed and paid up						
Share capital	100	6	100	6	100	6
101 (31 March 2016 : 101, 1 April 2015 : 101 equity shares of nil par value)						
	100	6	100	6	100	6

Movement in equity share capital

Particulars	As at 31 March 2017		As at 31 March 2016		As at 1 April 2015	
	Number	(INR'000)	Number	(INR'000)	Number	(INR'000)
At the commencement and at the end of the year	101	6	101	6	101	6
	101	6	101	6	101	6

Terms and rights attached to equity shares

The Company has only one class of shares referred to as equity shares having nil par value. Holder of each equity share is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

Details of shareholders holding more than 5% shares in the company

Particulars	As at 31 March 2017		As at 31 March 2016		As at 1 April 2015	
	Number	% of total shares	Number	% of total shares	Number	% of total shares
Jubilant Pharma Holding Inc - the holding company	101	100%	101	100%	101	100%
	101	100%	101	100%	101	100%

Jubilant Pharma Trading Inc
Notes to financial statements for the year 31 March 2017

Particulars	As at 31 March 2017		As at 31 March 2016		As at 1 April 2015	
	USD	(INR'000)	USD	(INR'000)	USD	(INR'000)
9. OTHER EQUITY						
Retained earnings						
Opening balance	1,140,708	72,671	487,663	30,167	-	-
Add: Net profit after tax transferred from Statement of Profit and Loss	317,805	21,315	653,045	42,504	487,663	30,479
Amount available for appropriation	1,458,513	93,986	1,140,708	72,671	487,663	30,479
Exchange differences on translation of foreign operations						
At the commencement of the year	-	2,901	-	-	-	-
Addition/(deduction) during the year	-	2,302	-	2,901	-	-
At the end of the year	-	599	-	2,901	-	-
	1,458,513	94,585	1,140,708	75,572	487,663	30,479
10. TRADE PAYABLES						
Trade payables-others	2,055,658	133,309	1,808,658	119,824	4,786,898	299,181
	2,055,658	133,309	1,808,658	119,824	4,786,898	299,181
11. OTHER CURRENT LIABILITIES						
Trade deposits and advances-current	-	-	-	-	279,140	17,447
Statutory dues	-	-	-	-	2,183	136
	-	-	-	-	281,323	17,583
12. CURRENT TAX LIABILITIES(NET)						
Provision for Income tax and wealth tax	821,379	53,266	618,443	40,972	262,588	16,411
	821,379	53,266	618,443	40,972	262,588	16,411

Jubilant Pharma Trading Inc
Notes to financial statements for the year 31 March 2017

	For the year ended on 31 March 2017		For the year ended on 31 March 2016	
	USD	(INR'000)	USD	(INR'000)
13. REVENUE FROM OPERATIONS				
Sales of products	18,371,257	1,232,322	19,877,673	1,295,972
Revenue from operations(gross)	18,371,257	1,232,322	19,877,673	1,295,972
Revenue from operations(net)	18,371,257	1,232,322	19,877,673	1,295,972
14. OTHER INCOME				
Other non-operating Income	4,625	310	6,500	438
	4,625	310	6,500	438
15. PURCHASE OF STOCK-IN-TRADE				
Purchase of stock-in-trade	17,002,922	1,142,784	17,910,954	1,168,445
	17,002,922	1,142,784	17,910,954	1,168,445
16. CHANGE IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND TRADED GOODS				
Stock at close -Traded goods	345,540	22,408	744,493	46,918
	345,540	22,408	744,493	46,918
Stock at commencement -Traded goods	744,493	46,918	1,248,756	79,109
	744,493	46,918	1,248,756	79,109
Increase/ (Decrease) In Stocks	(398,953)	(24,510)	(504,263)	(32,191)
17. OTHER EXPENSES				
Stores, spares, chemicals and packing materials consumed	100	7	-	-
Rates and taxes	3,352	224	1,000	66
Insurance	13,776	924	9,000	596
Advertisement, publicity and sales promotion	7,546	506	527	35
Travelling and other incidental expenses	8,233	553	11,475	762
Office expenses	210	13	82	5
Printing and stationery	74	5	-	-
Communication expenses	1,613	108	682	45
Auditors Remuneration - As Auditors	6,482	435	3,518	230
Legal, professional and consultancy charges	251,325	16,861	260,101	17,002
Freight and forwarding (Including ocean freight)	151,510	10,165	132,068	8,663
Subscription	4,000	268	4,000	269
Bank charges	1,294	87	1,495	98
Discounts and claims to customer and other selling expenses	5,253	352	33,466	2,156
	454,768	30,508	457,414	29,927